Deadline for abstracts: 6/07/2018

Deadline for late-breaker abstracts: 17/08/2018

The programme is of interest to clinical investigators from across the globe to review current research and discuss its implications for HIV management strategies. Although there has been steady progress in HIV drug treatment, significant challenges still remain, including persistence of elevated risk of non-AIDS morbidity, with potential for HIV and/or antiretroviral therapy (ART) as causes, paediatric and adolescent care, models of care for the ageing population, and treatment issues throughout less well-resourced parts of Europe and the rest of the world. The Congress is also moving into areas beyond treatment, such as prevention, with time in the programme focussed on pre-exposure prophylaxis (PrEP) and issues across Europe and beyond. The important role of people living with HIV in treatment decisions and self-management continues to feature, and we look forward to a number of perspectives in the programme from the community.

The programme maintains the plenary session presentation format. In addition to plenary presentations, the programme will include Keynote Lectures, the Lock Lecture, Industry Sessions and presentations based on abstracts submitted. The congress welcomes abstract submissions, and whilst only a small number can be accepted for oral presentation, we anticipate a sizeable display of Scientific Posters in the Congress Exhibition Hall throughout the Congress.